
Sign up to save your podcasts
Or


Dr. Scott Newsome’s Story: The Road From Caregiver to MS Provider and Researcher – Part 2 – Episode 97 – Transcript
Join us for the second part of our conversation with Dr. Scott Newsome. On this episode, Dr. Newsome will be back to talk about how his role as an MS caregiver has impacted his career today as an MS specialist. We’ll also learn more about what Dr. Newsome has been focusing on and his exciting current research.
As promised, learn more about the current clinical trial that Dr. Newsome is working on, the TREAT-MS Clinical Trial for Multiple Sclerosis Patients.The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Trial will help inform patients and the broader healthcare community on whether patients would most benefit from early, possibly more risky aggressive therapy or if starting with a less aggressive (and, often, less risky) therapy, followed by a switch if breakthrough disease activity occurs, is warranted. In addition, this study will help identify if there is a specific patient population or short-term biomarker(s) that is strongly predictive of long-term disability that can result from MS. For a deeper dive, view the Neurology Live video: Peers and Perspectives: The Induction vs. Escalation Approach to MS and the TREAT-MS Trial or you can also email TREAT-MS at [email protected].
By Can Do Multiple Sclerosis4.8
3232 ratings
Dr. Scott Newsome’s Story: The Road From Caregiver to MS Provider and Researcher – Part 2 – Episode 97 – Transcript
Join us for the second part of our conversation with Dr. Scott Newsome. On this episode, Dr. Newsome will be back to talk about how his role as an MS caregiver has impacted his career today as an MS specialist. We’ll also learn more about what Dr. Newsome has been focusing on and his exciting current research.
As promised, learn more about the current clinical trial that Dr. Newsome is working on, the TREAT-MS Clinical Trial for Multiple Sclerosis Patients.The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Trial will help inform patients and the broader healthcare community on whether patients would most benefit from early, possibly more risky aggressive therapy or if starting with a less aggressive (and, often, less risky) therapy, followed by a switch if breakthrough disease activity occurs, is warranted. In addition, this study will help identify if there is a specific patient population or short-term biomarker(s) that is strongly predictive of long-term disability that can result from MS. For a deeper dive, view the Neurology Live video: Peers and Perspectives: The Induction vs. Escalation Approach to MS and the TREAT-MS Trial or you can also email TREAT-MS at [email protected].

21,973 Listeners

43,680 Listeners

3,948 Listeners

112,321 Listeners

56,692 Listeners

147 Listeners

15 Listeners

9,257 Listeners

51 Listeners

124 Listeners

6,413 Listeners

58,256 Listeners

9 Listeners

114 Listeners

3,605 Listeners